Phase III Acceleration

Roche treats the Phase II diabetes result as a validation of its Carmot-derived obesity pipeline and moves rapidly toward pivotal trials. The 15.5% weight-loss figure is competitive enough to keep Roche in the GLP-1 obesity race, even though Lilly and Novo Nordisk remain the commercial leaders.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.